No, I didn't buy yesterday to answer you but I may as the price is appealing here. However, I do not have much faith that Mark P will hit his third quarter enrollment target and Invivo's approach to the control arm debate will need to pass mustard with the FDA.
News 
Market Data 
Discover 
